A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

被引：2
|
作者：
Song, Yuqin [1 ]
Li, Zengjun [2 ]
Wu, Huijing [3 ]
Jin, Jie [4 ]
Zhou, Hui [5 ]
Zhou, Keshu [6 ]
Zhang, Liling [7 ]
Peng, Zhigang [8 ]
Zhang, Zhiye [9 ]
Cen, Hong [10 ]
Jia, Youchao [11 ]
Shuang, Yuerong [12 ]
Li, Zhiming [13 ]
Yang, Haiyan [14 ]
Zou, Liqun [15 ]
Li, Zhifeng [16 ,17 ]
Zhang, Zhihui [18 ]
Li, Junmin [19 ]
Cao, Junning [20 ]
Qiu, Lugui [21 ]
Wu, Shaojie [22 ]
Gong, Tiejun [23 ]
Xu, Xiaohong [24 ]
Wang, Zhen [25 ]
Zhu, Jun [26 ]
机构：
[1] Peking Univ, Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
[3] Hubei Canc Hosp, Wuhan, Peoples R China
[4] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[5] Hunan Canc Hosp, Changsha, Peoples R China
[6] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[7] Huazhong Univ Sci & Technol, Canc Ctr, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[8] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Naning, Peoples R China
[9] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Oncol, Luoyang, Peoples R China
[10] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Med Oncol, Nanning, Peoples R China
[11] Hebei Univ, Dept Med Oncol, Affiliated Hosp, Baoding, Peoples R China
[12] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[13] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[14] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[15] Sichuan Univ, Dept Med Oncol, West China Sch Med, West China Hosp, Chengdu, Peoples R China
[16] Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China
[17] Xiamen Univ, Sch Med, Inst Hematol, Xiamen, Peoples R China
[18] Sichuan Canc Hosp & Inst, Chengdu, Peoples R China
[19] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China
[20] Fudan Univ, Shanghai Canc Ctr, Dept Lymphoma, Shanghai, Peoples R China
[21] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,Inst Hematol & Blood Dis H, Tianjin, Peoples R China
[22] Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China
[23] Harbin First Hosp, Inst Hematol & Oncol, Harbin, Peoples R China
[24] Nantong Univ, Dept Hematol & Lymphoma, Canc Hosp, Nantong, Peoples R China
[25] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[26] Peking Univ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Minist Educ, Beijing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180137
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
    Park, Byeong-Bae
    Kim, Won Seog
    Suh, Cheolwon
    Hong, Jung Yong
    Yang, Deok-Hwan
    Lee, Won Sik
    Do, Young Rok
    Koh, Young Il
    Won, Jong-Ho
    Kim, Min Kyoung
    Jo, Jae-Cheol
    Hyun, Shin Young
    Kim, Jeong-A
    Oh, Young Ha
    Lee, Seung-Sook
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3251 - 3257
  • [32] Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
    Bachy, Emmanuel
    Savage, Kerry J.
    Huang, Huiqiang
    Kwong, Yok-Lam
    Gritti, Giuseppe
    Zhang, Qingyuan
    Liberati, Anna Marina
    Cao, Junning
    Yang, Haiyan
    Hao, Siguo
    Hu, Jianda
    Zhou, Keshu
    Petrini, Mario
    Russo, Filomena
    Zhang, Huilai
    Sang, Wei
    Ji, Jie
    Ferreri, Andres Jose Maria
    Damaj, Gandhi Laurent
    Liu, Hui
    Zhang, Wei
    Ke, Xiaoyan
    Ghiggi, Chiara
    Huang, Sha
    Li, Xiaotong
    Yao, Hui
    Paik, Jason
    Noveotny, William
    Zhou, Wenxiao
    Zhu, Hongji
    Zinzani, Pier Luigi
    BLOOD ADVANCES, 2023, 7 (16) : 4435 - 4447
  • [33] Multicenter, open-label trial of PXD 101 in patients with relapsed/refractory peripheral T-cell lymphoma
    Zain, J. M.
    O'Connor, O.
    Zinzani, P. L.
    Norman, A.
    Brown, P. de Nully
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Multicenter, phase II study of bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial.
    Gressin, Remy
    Damaj, Gandhi Laurent
    Bouabdallah, Kamal
    Cartron, Guillaume
    Choufi, B.
    Gyan, Emmanuel
    Jaccard, Arnaud
    Park, Sophie
    De Colella, Jean-Marc Schiano
    Voillat, Laurent
    Joly, Bertrand
    Le Gouill, Steven
    Saad, Alain
    Sanhes, Laurence
    Moles-Moreau, Marie-Pierre
    Bubenheim, Michael
    Bene, Marie C.
    Martin, Antoine
    Marolleau, Jean Pierre
    Lamy, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas
    Fanale, Michelle A.
    Hagemeister, Fredrick B.
    Fayad, Luis
    Oki, Yasuhiro
    Fowler, Nathan
    Romaguera, Jorge
    Shah, Nina
    Chuang, Hubert
    Feng, Lei
    Horowitz, Sandra B.
    Wesson, Emily
    Hutto, Toni Y.
    Muzzafar, Tariq
    Samaniego, Felipe
    Davis, R. Eric
    BLOOD, 2014, 124 (21)
  • [36] Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4).
    Tao, Rong
    Fan, Lei
    Song, Yongping
    Hu, Yu
    Zhang, Wei
    Wang, Yafei
    Xu, Linxinyu
    Zhou, Hui
    Li, Jianyong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
    Querfeld, Christiane
    Kuzel, Timothy M.
    Kim, Youn H.
    Porcu, Pierluigi
    Duvic, Madeleine
    Musiek, Amy
    Rook, Alain H.
    Mark, Lawrence A.
    Pinter-Brown, Lauren
    Hamid, Oday
    Lin, Boris
    Bian, Ying
    Boye, Mark
    Day, Jeannette M.
    Rosen, Steven T.
    LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1474 - 1480
  • [38] Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
    Dai Maruyama
    Kunihiro Tsukasaki
    Toshiki Uchida
    Yoshinobu Maeda
    Hirohiko Shibayama
    Hirokazu Nagai
    Mitsutoshi Kurosawa
    Yoko Suehiro
    Kiyohiko Hatake
    Kiyoshi Ando
    Isao Yoshida
    Michihiro Hidaka
    Tohru Murayama
    Yoko Okitsu
    Norifumi Tsukamoto
    Masafumi Taniwaki
    Junji Suzumiya
    Kazuo Tamura
    Takahiro Yamauchi
    Ryuzo Ueda
    Kensei Tobinai
    Annals of Hematology, 2019, 98 : 131 - 142
  • [39] Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
    Maruyama, Dai
    Tsukasaki, Kunihiro
    Uchida, Toshiki
    Maeda, Yoshinobu
    Shibayama, Hirohiko
    Nagai, Hirokazu
    Kurosawa, Mitsutoshi
    Suehiro, Yoko
    Hatake, Kiyohiko
    Ando, Kiyoshi
    Yoshida, Isao
    Hidaka, Michihiro
    Murayama, Tohru
    Okitsu, Yoko
    Tsukamoto, Norifumi
    Taniwaki, Masafumi
    Suzumiya, Junji
    Tamura, Kazuo
    Yamauchi, Takahiro
    Ueda, Ryuzo
    Tobinai, Kensei
    ANNALS OF HEMATOLOGY, 2019, 98 (01) : 131 - 142
  • [40] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
    Mehta-Shah, Neha
    Zinzani, Pier Luigi
    Jacobsen, Eric D.
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Gritti, Giuseppe
    Pinter-Brown, Lauren C.
    Izutsu, Koji
    Bentur, Ohad S.
    Sidransky, David
    Brammer, Jonathan E.
    Pro, Barbara
    Fox, Christopher P.
    Horwitz, Steven
    BLOOD, 2024, 144 : 3061 - 3062
12345